< Back to Thought Leadership

CMS 2023 Medicare DSH Ruling Vacated

On August 28, 2026, the U.S. District Court for the District of Columbia vacated CMS’s 2023 rule addressing the treatment of Medicare Advantage (Part C) inpatient days in the Medicare DSH calculation during the 2005-2013 fiscal years.  Click here to read the court’s recent decision.

Issue at Hand

CMS’s 2023 rule required including Part C days in the Medicare fraction and excluding them from the numerator of the Medicaid fraction during the 2005-2013 period. The placement of these days can affect a hospital’s DSH percentage.

What the Court Decided

In a September 2025 decision, the court held that the 2023 rule was unlawful, saying it constituted as retroactive rulemaking under 42 U.S.C. § 1395hh(e)(1)(A). The court held that the rule was arbitrary and capricious because CMS did not adequately address commenters’ concerns about the financial impact of applying the policy retroactively.

In its August 28, 2026 remedy decision, the court vacated the 2023 rule and remanded the matter to the Secretary of Health and Human Services (HHS) for further proceedings.

The court rejected HHS’s position that relief should be limited to Montefiore. The court concluded that vacatur sets aside the rule itself, rather than providing relief only to the named plaintiff.  This allows the possibility for a remedy for additional DSH hospitals.

The court did not order CMS to recalculate Montefiore’s DSH payment using any particular methodology. The court explained that directing a specific payment calculation would be an extraordinary remedy. They left the Secretary room to consider a lawful path forward on remand.

Next Steps

  1. HHS will likely appeal the decision to the U.S. Court of Appeals.
  2. CMS could issue instructions to MACs concerning the affected cost reporting periods, although the court did not require a particular calculation or payment approach.
  3. PRRB and court proceedings involving related Part C/DSH claims may remain stayed or otherwise be affected while the appellate and remand processes proceed.

Please reach out to one of our Medicare DSH experts listed below if you have any questions or concerns.

Nick Ficklin, CPA, FHFMA, Director

Shawn Barney, CPA, CHFP, Manager

Stacey Basalla, CPA, CHFP, Manager

Lisa Deaton, Manager

Share this article

Bonus depreciation for thoroughbred owners

100% Bonus Depreciation: Finding the Right Tax Strategy for Your Thoroughbred Operation

By Heather Sunseri, CPA, Senior Manager at Blue & Co. For thoroughbred owners and breeders, tax strategy can be just as important as bloodlines and training decisions. And when President […]

Learn More
Headshot of Kurt Beier, the new Managing Partner at Blue & Co., LLC

Blue & Co. Elects Kurt Beier as Next Managing Director

Beier to succeed Brad Shaw effective January 1, 2027, following a planned two-year succession process. CARMEL, Ind. (October 6, 2026) – Blue & Co., LLC, a top-60 accounting and advisory […]

Learn More
quality of earnings

Why a Quality of Earnings Report Matters Before You Buy

By Jonah Gjertson, CVA, Senior Consultant at Blue & Co. Buying a business is a complicated process with material financial implications each step of the way. There are many decisions […]

Learn More
Share this article
Share this article